Table 4:

PMPRB therapeutic evaluations and CDR/pCODR listing recommendations

CDR/pCODR listing recommendationTherapeutic evaluation by PMPRB
Breakthrough or substantial improvementModerate improvement (2010 onward)Moderate, little or no improvement (before 2010)Slight or no improvement (2010 onward)No evaluation
List in formulary in a manner similar to other drugs in the same class00100
List subject to conditions11442
Do not list0274*0
  • Note: CDR = Common Drug Review, pCODR = pan-Canadian Oncology Drug Review, PMPRB = Patented Medicine Prices Review Board.

  • * For 1 of these drugs, the recommendation was that the drug not be listed at the price submitted by the company.